^
    Back
    Association details:
    Biomarker:ALK positive
    Cancer:T Cell Non-Hodgkin Lymphoma
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Non-Hodgkin’s Lymphoma)
    New
    Excerpt:
    XALKORI is a kinase inhibitor indicated for the treatment of…pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive.
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Eur J Cancer
    Title:

    Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcSé-crizotinib trial

    Published date:
    07/17/2023
    Excerpt:
    In the 24 patients with an evaluable response, the response rate at 8 weeks was 67% (95% CI: 47-82%)….The median duration of response was 43.3 months (95% CI: 8.3-not reached). The 3-year progression-free and overall survival rates were 40% (95% CI: 23-59%) and 63% (95% CI: 43-79%)....Crizotinib shows efficacy and an acceptable safety profile in ALK+ ALCL relapsed/refractory patients.
    DOI:
    10.1016/j.ejca.2023.112984
    Trial ID:
    AcSé